Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Elotuzumab in Combination with an Immunomodulatory Agent (IMID) in Patients with Multiple Myeloma Refractory to Imids and/or Daratumumab: A Single-Institution Analysis

Ariel F Grajales-Cruz, MD, Cristian Ivan Rodriguez Arocho, MD, Ashley Rose, MD, Jamie Shapiro, PharmD, Elizabeth Finley-Oliver, Kenneth H. Shain, MD PhD, Jason B. Brayer, PhDMD, Taiga Nishihori, MD, Leonel Ochoa, MD, Omar Alexis Castaneda Puglianini, MD, Melissa Alsina, MD, Rachid Baz, MD

Blood (2019) 134 (Supplement_1): 3183.

https://doi.org/10.1182/blood-2019-129021

Published: 2019

Journal Articles

Panobinostat As a Maintenance Therapy after Autologous Hematopoietic Cell Transplantation for Patients with Multiple Myeloma

Taiga Nishihori, MD, Rachid Baz, MD, Leonel Ochoa, MD, Omar Alexis Castaneda Puglianini, MD, Kenneth H. Shain, MD PhD, Jason B. Brayer, PhDMD, Frederick L. Locke, MD, Jongphil Kim, PhD, Jinming Song, MD PhD, Michael Dumala, Melissa Alsina, MD

Blood (2019) 134 (Supplement_1): 3189.

https://doi.org/10.1182/blood-2019-131451

Published: 2019

Journal Articles

A Phase II Trial Evaluating the Use of the Histone Deacetylase Inhibitor Panobinostat for Graft-Versus-Host Disease (GVHD) Prevention

Lia Perez, MD, Hugo F. Fernandez, MD, Farhad Khimani, MBBS, Ernesto Ayala, MD, Mohamed A Kharfan-Dabaja, MD, Asmita Mishra, MD, Leonel Ochoa, MD, Brian C. Betts, MD, Joseph Pidala, MD PhD, Claudio Anasetti, MD

Blood (2017) 130 (Supplement 1): 1985.

https://doi.org/10.1182/blood.V130.Suppl_1.1985.1985

Published: 2017

Journal Articles

Response Adapted Therapy Using Single Agent Lenalidomide in Older Adults with Newly Diagnosed Standard Risk Multiple Myeloma

Rachid Baz, MD, Melissa Alsina, MD, Kenneth H. Shain, MD, PhD, Jennifer Paleveda, Nancy Hillgruber, RN, Elizabeth Finley-Oliver, RN, Leonel Ochoa, MD, Taiga Nishihori, MD, William Dalton, PhD, MD, Daniel Sullivan, MD

Blood (2012) 120 (21): 4060.

https://doi.org/10.1182/blood.V120.21.4060.4060

Published: 2012

Journal Articles

Oral Weekly Cyclophosphamide in Combination with Pomalidomide and Dexamethasone for Relapsed and Refractory Myeloma: Report of the Dose Escalation Cohort

Rachid Baz, MD, Kenneth H. Shain, MD, PhD, Melissa Alsina, MD, Lisa A Nardelli, Taiga Nishihori, MD, Leonel Ochoa, MD, Thomas Martin, MD, Sundar Jagannath, MD, William Dalton, PhD, MD, Daniel M Sullivan, MD

Blood (2012) 120 (21): 4062.

https://doi.org/10.1182/blood.V120.21.4062.4062

Published: 2012

Journal Articles

Updated Results of Phase II Study of Cyclophosphamide(Cy), Bortezomib(Bz), Pegylated Doxorubicin(DOX), and Dexamethasone(dex), (CVDD), in Patients with Newly Diagnosed Myeloma:an Effective Induction Regimen for High Risk Disease

Melissa Alsina, MD, Rachid Baz, MD, Kenneth H. Shain, MD, PhD, Leonel Ochoa, MD, Taiga Nishihori, MD, Daniel M Sullivan, MD, Binglin Yue, Jongphil Kim, PhD, William Dalton, PhD, MD

Blood (2012) 120 (21): 4071.

https://doi.org/10.1182/blood.V120.21.4071.4071

Published: 2012

Journal Articles

Sequence of Therapy in Multiple Myeloma: Does It Matter? Retrospective Evaluation of Patients with Multiple Myeloma Who Have Received Bortezomib Followed by Lenalidomide or Vice Versa,

Amila M Patel, PharmD, Viet Q. Ho, PharmD, BCOP, Kenneth H. Shain, MD, PhD, Daniel Sullivan, MD, Melissa Alsina, MD, Leonel Ochoa, Taiga Nishihori, MD, Benjamin Djulbegovic, MD, PhD, William Dalton, PhD, MD, Rachid Baz, MD

Blood (2011) 118 (21): 3979.

https://doi.org/10.1182/blood.V118.21.3979.3979

Published: 2011

Journal Articles

Sirolimus/Tacrolimus Facilitates Preferential Recovery of Regulatory T Cells (Treg) After Allogeneic Hematopoietic Cell Transplantation (HCT), and Is More Effective Than Methotrexate/Tacrolimus in Preventing Grade II-IV Acute Graft Vs. Host Disease (GVHD) and Moderate to Severe Chronic Gvhd

Joseph Pidala, MD, MS, Jongphil Kim, PhD, Heather Jim, PhD, Hugo F. Fernandez, MD, Marcie Tomblyn, MD, MS, Mohamed A Kharfan-Dabaja, MD, Brian C. Betts, MD, Taiga Nishihori, MD, Mian Xu, William E. Janssen, PhD, Frederick L Locke, MD, Ernesto Ayala, MD, Lia Perez, MD, Janelle Perkins, PharmD, Teresa Field, MD, PhD, Leonel Ochoa, Melissa Alsina, MD, Claudio Anasetti, MD

Blood (2011) 118 (21): 323.

https://doi.org/10.1182/blood.V118.21.323.323

Published: 2011

Journal Articles

Alternative Dosing of Cyclophosphamide, Bortezomib and Corticosteroids (CyBorD) for Relapsed/Refractory Multiple Myeloma

Viet Q. Ho, PharmD, BCOP, Elizabeth Finley-Oliver, RN, Kenneth H. Shain, MD, PhD, Melissa Alsina, MD, Leonel Ochoa, Taiga Nishihori, MD, Benjamin Djulbegovic, MD, PhD, Rachid Baz, MD

Blood (2011) 118 (21): 5142.

https://doi.org/10.1182/blood.V118.21.5142.5142

Published: 2011

Journal Articles

A Phase 2 Study of Bortezomib Plus High-Dose Melphalan (Mel/Vel) Conditioning for Autologous Hematopoietic Cell Transplantation In Multiple Myeloma,

Taiga Nishihori, MD, Leonel Ochoa, Joseph Pidala, MD, MS, Kenneth H. Shain, MD, PhD, Rachid Baz, MD, Christine Simonelli, RN, Dan Sullivan, Claudio Anasetti, MD, Melissa Alsina, MD

Blood (2011) 118 (21): 4158.

https://doi.org/10.1182/blood.V118.21.4158.4158

Published: 2011

Journal Articles

Outcomes Analysis of Doublets of Novel Agents with Corticosteroids Versus Regimens with 3 or More Agents for Multiple Myeloma (MM): A Retrospective Analysis

Rachid Baz, MD, Amila M Patel, PharmD, Viet Q. Ho, PharmD, BCOP, Kenneth Shain, MD, PhD, Melissa Alsina, MD, Taiga Nishihori, MD, Jose Leonel Ochoa-Bayona, M.D., Daniel Sullivan, MD, Benjamin Djulbegovic, MD, PhD, William S. Dalton, PhD, MD

Blood (2011) 118 (21): 1878.

https://doi.org/10.1182/blood.V118.21.1878.1878

Published: 2011

Journal Articles

Phase II Study of a Novel Reduced Toxicity Preparative Regimen for Hematopoietic Cell Allografting Combining Pentostatin (Nipent) and Targeted Doses of Intravenous Busulfan (Busulfex) with or without Rituximab (PB±R) Using a Novel Principle of CD4-Guided Immune Suppression

Mohamed A Kharfan-Dabaja, MD, Claudio Anasetti, MD, Nathalie Luis, B.S., Linda Brand, R.N., Janelle Perkins, PharmD, Hugo F. Fernandez, MD, Jose Leonel Ochoa-Bayona, M.D., Taiga Nishihori, MD, Lia E Perez, MD, Ernesto Ayala, MD, Javier Pinilla-Ibarz, MD, PhD, Lubomir Sokol, MD, PhD, Joseph Pidala, MD, MS, Frederick L Locke, MD, Eduardo M. Sotomayor, Teresa Field, MD, PhD, Marcie Tomblyn, MD, MS

Blood (2011) 118 (21): 3022.

https://doi.org/10.1182/blood.V118.21.3022.3022

Published: 2011

Journal Articles

Updated Results of the Phase II Study of Pegylated Liposomal Doxorubicin (PLD), Low Dose Dexamethasone (DEX) and Lenalidomide (LEN) In Patients with Newly Diagnosed (ND) Multiple Myeloma (MM)

Rachid Baz, MD, Mohamad A Hussein, MD, Daniel Sullivan, MD, Jose-Leonel Ochoa-Bayona, M.D., Monique A Hartley, MD, Kenneth Shain, MD, PhD, Taiga Nishihori, MD, Jennifer Paleveda, Kara Kosakowski, William S. Dalton, PhD, MD, Melissa Alsina, MD

Blood (2010) 116 (21): 3054.

https://doi.org/10.1182/blood.V116.21.3054.3054

Published: 2010

Journal Articles

Treatments and Outcomes of Patients with Multiple Myeloma (MM) Older Than 75 Years of Age: A Single Institution Experience

Elizabeth Finley-Oliver, RN, Kenneth Shain, MD, PhD, Taiga Nishihori, MD, Jose-Leonel Ochoa-Bayona, M.D., Melissa Alsina, MD, Daniel Sullivan, MD, William S. Dalton, PhD, MD, Rachid Baz, MD

Blood (2010) 116 (21): 4756.

https://doi.org/10.1182/blood.V116.21.4756.4756

Published: 2010

Journal Articles

Prospective Trial of Pre-Transplant 5-Azacitidine on Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndrome and CMML

Teresa Field, MD, PhD, Janelle Perkins, PharmD, Taiga Nishihori, MD, Joseph Pidala, Hugo F. Fernandez, MD, Marcie Tomblyn, MD, MS, Mohamed Kharfan-Dabaja, MD, Lia Perez, MD, Rami S. Komrokji, MD, Jeffrey E. Lancet, MD, Jongphil Kim, Ernesto Ayala, MD, Melissa Alsina, MD, Jose-Leonel ochoa-Bayona, M.D., Alan F. List, Claudio Anasetti, MD

Blood (2010) 116 (21): 1333.

https://doi.org/10.1182/blood.V116.21.1333.1333

Published: 2010

Journal Articles

Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia In Patients up to Age 75: Comparison of Survival In Patients with An Available Donor Compared to Patients without a Donor

Teresa Field, MD, PhD, Janelle Perkins, PharmD, Taiga Nishihori, MD, Joseph Pidala, Hugo F. Fernandez, MD, Marcie Tomblyn, MD, MS, Mohamed Kharfan-Dabaja, MD, Lia Perez, MD, Jeffrey E. Lancet, MD, Rami S. Komrokji, MD, Jose-Leonel ochoa-Bayona, M.D., Melissa Alsina, MD, Ernesto Ayala, MD, Jongphil Kim, Alan F. List, Claudio Anasetti, MD

Blood (2010) 116 (21): 2381.

https://doi.org/10.1182/blood.V116.21.2381.2381

Published: 2010

Journal Articles

Sirolimus Yields High Response Rates in Hematopoietic Allograft Recipients with Steroid-Refractory Acute Graft-Versus-Host Disease.

Joseph A. Pidala, MD, Daanish Hoda, Norma Salgado-Vila, Jongphil Kim, PhD, Janelle Perkins, PharmD, Ryan Bookout, PharmD, Teresa Field, MD, PhD, Lia Perez, MD, Ernesto Ayala, MD, J. Leonel Ochoa-Bayona, Jyotishankar Raychaudhuri, Melissa Alsina, MD, John N Greene, MD, William E. Janssen, PhD, Hugo F. Fernandez, MD, Claudio Anasetti, MD, Mohamed A Kharfan-Dabaja, MD

Blood (2009) 114 (22): 2235.

https://doi.org/10.1182/blood.V114.22.2235.2235

Published: 2009

Journal Articles

Evaluation of 243 Patients with Myelodysplastic Syndrome (MDS) Referred for Hematopoietic Cell Transplant (HCT) Including Donor Availability and HCT Outcomes.

Teresa Field, MD, PhD, Janelle Perkins, PharmD, Mohamed A Kharfan-Dabaja, MD, Hugo F. Fernandez, MD, Lia Perez, MD, J. Leonel Ochoa-Bayona, MD, Jeffrey E Lancet, MD, Rami S. Komrokji, MD, Melissa Alsina, MD, Ernesto Ayala, MD, Alan F List, MD, Claudio Anasetti, MD

Blood (2009) 114 (22): 3383.

https://doi.org/10.1182/blood.V114.22.3383.3383

Published: 2009

Journal Articles

Hypoalbuminemia (< 3.0 g/dl) and Poor Karnofsky Performance Score (<80) at Day 90 Following Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT) Are Independent Predictors of Worse Non-Relapse Survival (NRS) and Overall Survival (OS): A Multivariable Analysis Approach of Various Clinical, Laboratory and Pharmacologic Parameters

Mohamed A Kharfan-Dabaja, MD, Julio C. Chavez, Eduardo Ivan Fernandez-Vertiz, Daohai Yu, Weiwei Zhu, Janelle Perkins, Teresa Field, Ernesto Ayala, Hugo F. Fernandez, Melissa Alsina, Lia Perez, Jyotishankar Raychaudhuri, J. Leonel Ochoa-Bayona, Linda Brand, Dan Sullivan, Claudio Anasetti

Blood (2008) 112 (11): 4329.

https://doi.org/10.1182/blood.V112.11.4329.4329

Published: 2008

Journal Articles

Age Is the Strongest Independent Prognostic Factor in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: Moffitt Cancer Center Experience

Blood (2008) 112 (11): 4435.

https://doi.org/10.1182/blood.V112.11.4435.4435

Published: 2008

NARROW

Elotuzumab in Combination with an Immunomodulatory Agent (IMID) in Patients with Multiple Myeloma Refractory to Imids and/or Daratumumab: A Single-Institution Analysis

Panobinostat As a Maintenance Therapy after Autologous Hematopoietic Cell Transplantation for Patients with Multiple Myeloma

A Phase II Trial Evaluating the Use of the Histone Deacetylase Inhibitor Panobinostat for Graft-Versus-Host Disease (GVHD) Prevention

Response Adapted Therapy Using Single Agent Lenalidomide in Older Adults with Newly Diagnosed Standard Risk Multiple Myeloma

Oral Weekly Cyclophosphamide in Combination with Pomalidomide and Dexamethasone for Relapsed and Refractory Myeloma: Report of the Dose Escalation Cohort

Updated Results of Phase II Study of Cyclophosphamide(Cy), Bortezomib(Bz), Pegylated Doxorubicin(DOX), and Dexamethasone(dex), (CVDD), in Patients with Newly Diagnosed Myeloma:an Effective Induction Regimen for High Risk Disease

Sequence of Therapy in Multiple Myeloma: Does It Matter? Retrospective Evaluation of Patients with Multiple Myeloma Who Have Received Bortezomib Followed by Lenalidomide or Vice Versa,

Sirolimus/Tacrolimus Facilitates Preferential Recovery of Regulatory T Cells (Treg) After Allogeneic Hematopoietic Cell Transplantation (HCT), and Is More Effective Than Methotrexate/Tacrolimus in Preventing Grade II-IV Acute Graft Vs. Host Disease (GVHD) and Moderate to Severe Chronic Gvhd

Alternative Dosing of Cyclophosphamide, Bortezomib and Corticosteroids (CyBorD) for Relapsed/Refractory Multiple Myeloma

A Phase 2 Study of Bortezomib Plus High-Dose Melphalan (Mel/Vel) Conditioning for Autologous Hematopoietic Cell Transplantation In Multiple Myeloma,

Outcomes Analysis of Doublets of Novel Agents with Corticosteroids Versus Regimens with 3 or More Agents for Multiple Myeloma (MM): A Retrospective Analysis

Phase II Study of a Novel Reduced Toxicity Preparative Regimen for Hematopoietic Cell Allografting Combining Pentostatin (Nipent) and Targeted Doses of Intravenous Busulfan (Busulfex) with or without Rituximab (PB±R) Using a Novel Principle of CD4-Guided Immune Suppression

Updated Results of the Phase II Study of Pegylated Liposomal Doxorubicin (PLD), Low Dose Dexamethasone (DEX) and Lenalidomide (LEN) In Patients with Newly Diagnosed (ND) Multiple Myeloma (MM)

Treatments and Outcomes of Patients with Multiple Myeloma (MM) Older Than 75 Years of Age: A Single Institution Experience

Prospective Trial of Pre-Transplant 5-Azacitidine on Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndrome and CMML

Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia In Patients up to Age 75: Comparison of Survival In Patients with An Available Donor Compared to Patients without a Donor

Sirolimus Yields High Response Rates in Hematopoietic Allograft Recipients with Steroid-Refractory Acute Graft-Versus-Host Disease.

Evaluation of 243 Patients with Myelodysplastic Syndrome (MDS) Referred for Hematopoietic Cell Transplant (HCT) Including Donor Availability and HCT Outcomes.

Age Is the Strongest Independent Prognostic Factor in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: Moffitt Cancer Center Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only